[Webinar] How to better optimize an oncology drug discovery program
Register for this webinar discussing how conventional and innovative integrated technological skills should be incorporated into an oncology program.Read more
Read the full press release about our very good results in 2021 & an attractive outlook for 2022 for the group & our BUs Service, Biotech & AI.
Abzena x Alira Health x Oncodesign: unveil unique integrated solution with specialist services, from biologics discovery to clinical & commercial manufacturing
Read all the details of the collaboration agreement for R&D of a new personalized cancer treatment for aggressive and untreatable tumors.
Find all the 2021 financial information: 2021 turnover of €31.3M, up by 22%, and expects to break even and dive into the BU financial results
Oncodesign announces all the regulatory dates as far as financial information is concerned. Let's have a look :)
Protection of RIPK2 inhibitors resulting from Nanocyclix® technology with patents granted on the main international markets: Europe, United States, Japan and Eurasia
Oncodesign adds a new high-level competence to its COMEX to achieve its external growth objectives with Karine Lignel.
Under this agreement, Oncodesign will be responsible for identification, chemical synthesis & optimization of Nanocyclix® drug candidates & their early-stage analysis. TiumBio will be responsible for the advanced evaluation of fibrotic efficacy of the drug candidates.
Read all the financial information of Oncodesign and its Business Units Service, Biotech and Artificial Intelligence.
Group turnover up by 33% at €15.8M. Despite the global health crisis, which continues to limit international travel...
Oncodesign strenghens its Board by appointing Aline Aubertin as new independent director.
Discover the alliance of experts in radiopharmaceuticals: an innovative offer in therapeutic development in nuclear medicine from the validation of therapeutic targets, the generation of radiolabeled biological vectors, the optimization of leads, the generation of drug candidates to IND, the design and management of clinical trials.